In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …